Starting the electrical therapy Optune Gio during radiation therapy and chemotherapy, rather than after it as indicated, did not extend…
Articles by Steve Bryson, PhD
Adults in the U.S. now have a new generic drug option — Bortezomib for Injection, an equivalent of the approved…
Nearly two-thirds of adults ages 80 and older with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),…
Treatment with Revolution Medicines‘ oral daraxonrasib more than doubled overall survival versus standard chemotherapy among adults with previously treated…
In adults newly diagnosed with a type of blood cancer called core-binding factor acute myeloid leukemia (CBF-AML), genetic mutations…
One-time treatment with vispa-cel (CB-010), Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, resulted in durable responses in people with…
Canada’s Drug Agency (CDA-AMC) has recommended that Canadian public drug plans cover the cost of the gynecological cancer therapy…
All three adults with high-risk acute myeloid leukemia (AML) who had already been given 3-4 lines of cancer treatment responded…
The U.S. Food and Drug Administration has approved a new rapid diagnostic test to identify patients with treatment-resistant acute leukemias…
The gynecological cancer therapy Elahere (mirvetuximab soravtansine) is now approved in Canada for adults with platinum-based, chemotherapy-resistant, ovarian, fallopian…